AC007382.1 | Uncharacterized protein | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
AC018816.3 | Uncharacterized protein | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
AC142381.1 | | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
ACER2 | Alkaline ceramidase 2 | Enzymes Predicted membrane proteins
| ![](/images/14092/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/14092/39468_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
ALG1L | ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase-like | | ![](/images/36108/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/36108/78420_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
ATP1A4 | ATPase, Na+/K+ transporting, alpha 4 polypeptide | Enzymes Predicted membrane proteins
| ![](/images/33628/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/33628/79047_B_5_3_rna_selected_60x60.jpg) | Tissue enhanced |
BDKRB1 | Bradykinin receptor B1 | G-protein coupled receptors Predicted membrane proteins
| ![](/images/2935/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2935/8078_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
BMP3 | Bone morphogenetic protein 3 | Plasma proteins Predicted secreted proteins
| ![](/images/45344/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/45344/103806_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
BTBD16 | BTB (POZ) domain containing 16 | | ![](/images/40529/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/40529/85762_B_9_8_rna_selected_60x60.jpg) | Tissue enhanced |
CCR4 | Chemokine (C-C motif) receptor 4 | CD markers G-protein coupled receptors Predicted membrane proteins
| ![](/images/31613/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/31613/68831_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
CCR8 | Chemokine (C-C motif) receptor 8 | CD markers G-protein coupled receptors Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CHI3L1 | Chitinase 3-like 1 (cartilage glycoprotein-39) | Cancer-related genes Disease related genes Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CLEC3A | C-type lectin domain family 3, member A | Predicted secreted proteins
| ![](/images/51511/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/51511/127859_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
CLLU1OS | Chronic lymphocytic leukemia up-regulated 1 opposite strand | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CTHRC1 | Collagen triple helix repeat containing 1 | Disease related genes Predicted secreted proteins
| | ![](/images/61896/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/59806/140822_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
CXCL1 | Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) | Cancer-related genes Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CXCL5 | Chemokine (C-X-C motif) ligand 5 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/65474/146784_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
CXCL6 | Chemokine (C-X-C motif) ligand 6 | Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
CYP24A1 | Cytochrome P450, family 24, subfamily A, polypeptide 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets
| ![](/images/22261/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22261/51209_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
DKK1 | Dickkopf WNT signaling pathway inhibitor 1 | Predicted secreted proteins
| ![](/images/18995/ihc_selected_60x60.jpg) | ![](/images/18995/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/18995/43795_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
DUOXA2 | Dual oxidase maturation factor 2 | Disease related genes Predicted membrane proteins
| ![](/images/11085/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/11085/28066_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
EDARADD | EDAR-associated death domain | Disease related genes
| ![](/images/18836/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18836/42076_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
FAM150A | Family with sequence similarity 150, member A | Predicted secreted proteins
| ![](/images/27368/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/27368/58662_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
FOXQ1 | Forkhead box Q1 | Cancer-related genes Transcription factors
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/66032/149456_A_6_5_rna_selected_60x60.jpg) | Tissue enhanced |
FSTL4 | Follistatin-like 4 | Predicted secreted proteins
| ![](/images/45920/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/45920/105032_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
GPR110 | G protein-coupled receptor 110 | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| ![](/images/38438/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/38438/81850_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
HAS3 | Hyaluronan synthase 3 | Enzymes Predicted membrane proteins
| | ![](/images/33850/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/33850/69312_A_6_4_rna_selected_60x60.jpg) | Tissue enhanced |
HOXA1 | Homeobox A1 | Disease related genes Transcription factors
| ![](/images/4933/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/4933/17308_B_5_1_rna_selected_60x60.jpg) | Tissue enhanced |
HOXB8 | Homeobox B8 | Transcription factors
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
HPGD | Hydroxyprostaglandin dehydrogenase 15-(NAD) | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | ![](/images_static/na_center.gif) | ![](/images/5679/ihc_cell_selected_60x60.jpg) | ![](/images/5679/20207_A_4_7_rna_selected_60x60.jpg) | Tissue enhanced |
HS6ST3 | Heparan sulfate 6-O-sulfotransferase 3 | Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/51513/127124_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
IL17A | Interleukin 17A | Cancer-related genes Plasma proteins Predicted secreted proteins
| ![](/images/52258/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/52258/119542_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
IL1RAPL2 | Interleukin 1 receptor accessory protein-like 2 | Predicted membrane proteins
| ![](/images/36128/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/36128/74704_B_9_6_rna_selected_60x60.jpg) | Tissue enhanced |
IL26 | Interleukin 26 | Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
IL9R | Interleukin 9 receptor | CD markers Predicted membrane proteins
| ![](/images/10497/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/10497/27232_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
KRT17 | Keratin 17 | Cancer-related genes Disease related genes Plasma proteins
| | ![](/images_static/na_center.gif) | | ![](/images/29/378_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
KRTAP5-9 | Keratin associated protein 5-9 | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
MMP13 | Matrix metallopeptidase 13 (collagenase 3) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
MMP2 | Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| ![](/images/1939/ihc_selected_60x60.jpg) | ![](/images/1939/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/1939/7517_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
MSX2 | Msh homeobox 2 | Disease related genes Plasma proteins Transcription factors
| ![](/images/5652/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5652/20969_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
MYO3B | Myosin IIIB | Enzymes
| ![](/images/15745/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/15745/35211_B_2_4_rna_selected_60x60.jpg) | Tissue enhanced |
OSTN | Osteocrin | Predicted secreted proteins
| ![](/images/30878/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images/30878/ihc_cell_selected_60x60.jpg) | ![](/images/24997/56994_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
P2RX1 | Purinergic receptor P2X, ligand-gated ion channel, 1 | Predicted membrane proteins
| ![](/images/6813/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/6813/17757_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
P4HA3 | Prolyl 4-hydroxylase, alpha polypeptide III | Enzymes Predicted secreted proteins
| ![](/images/7897/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/7897/22599_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
PCP4 | Purkinje cell protein 4 | | ![](/images/5792/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/5792/20420_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
PCP4L1 | Purkinje cell protein 4 like 1 | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
PI16 | Peptidase inhibitor 16 | Plasma proteins Predicted membrane proteins
| ![](/images/43763/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/43763/96375_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/1335/ihc_cell_selected_60x60.jpg) | ![](/images/1335/3886_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
RP11-1012A1.4 | | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
RP11-680G10.1 | Uncharacterized protein | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |